Riktkurs.nu
EN | SV
There is a problem with the stock price data. Our supplier is working to solve the issue.
VNV GlobalMid Cap
Stockholm Stock Exchange | Mid Cap
Xvivo Perfusion
+47.19%
Latest
+49.35%
3 months
Bryan GarnierPareto SecuritiesSEBSEB EquitiesCarnegieDanske BankDanske Bank Markets

Price Targets For Xvivo Perfusion

AnalystPrice TargetDateUpside
Bryan Garnier340 SEKNov 13
+47.19%
Pareto Securities280 SEKOct 25
SEB415 SEKSep 29
SEB Equities410 SEKJun 21
Carnegie385 SEKApr 25
Danske Bank403 SEKOct -22
Danske Bank Markets448 SEKJun -21

About The Company

XVIVO is a medical technology company firmly rooted within medical science with more than 20 years of experience in the transplantation area.
Xvivo Perfusion

The information on Riktkurs.nu is for general information purposes only. Riktkurs.nu makes no guarantees of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to Riktkurs.nu or the information, products, services, or related information on Riktkurs.nu for any purpose. The recipient is recommended to complete his or her decision basis with the material deemed necessary. We reserve us for all types of errors as well as any malfunctions of the website. The information on Riktkurs.nu should not be seen as a recommendation to buy or sell a security.
© Riktkurs.nu 2023